Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: A multicenter phase II clinical trial.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 1013-1013 ◽  
Author(s):  
F. Dalenc ◽  
M. Campone ◽  
P. Hupperets ◽  
R. O'Regan ◽  
C. Manlius ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Metastatic Breast ◽  
Phase Ii Clinical Trial ◽  
Weekly Paclitaxel ◽  
Multicenter Phase

Final Results of a Phase II Clinical Trial of Weekly Docetaxel in Combination with Capecitabine in Anthracycline-Pretreated Metastatic Breast Cancer

2004 ◽  
Vol 5 (4) ◽  
pp. 287-292 ◽  
Author(s):  
John R. Mackey ◽  
Katia S. Tonkin ◽  
Sheryl L. Koski ◽  
Andrew G. Scarfe ◽  
Michael G.B. Smylie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Metastatic Breast ◽  
Phase Ii Clinical Trial ◽  
Weekly Docetaxel

Preliminary Results or a Phase II Clinical Trial Utilising Tru-Scint® AD™ in Primary and Metastatic Breast Cancer

1994 ◽  
Vol 19 (10) ◽  
pp. 932
Author(s):  
A. J.B. McEwan ◽  
G. D. MacLean ◽  
L. Golberg ◽  
K. Golberg ◽  
G. R. Boniface ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Metastatic Breast Cancer ◽  
Phase Ii ◽  
Metastatic Breast ◽  
Phase Ii Clinical Trial ◽  
Preliminary Results
Sign in / Sign up

Export Citation Format

Share Document